CytoDyn (CYDY) EBT (2010 - 2026)

CytoDyn (CYDY) has 17 years of EBT data on file, last reported at -$4.7 million in Q1 2026.

• Quarterly EBT rose 1.43% year-over-year to -$4.7 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was -$38.8 million (down 447.46% YoY) and the FY2025 annual result came in at $3.7 million, up 107.51% from the prior year.
• EBT climbed to -$4.7 million in Q1 2026, from -$22.6 million in the prior quarter.
• In the past five years, EBT ranged from a high of $19.2 million in Q3 2024 to a low of -$84.1 million in Q2 2022.
• A 5-year average of -$16.7 million and a median of -$11.9 million in 2024 frame the typical range for EBT.
• Annual changes were most pronounced in 2024 — EBT jumped 266.17% — and 2025, when it tumbled 374.14%.
• Tracing CYDY's EBT over 5 years: stood at -$26.5 million in 2022, then soared by 63.91% to -$9.6 million in 2023, then soared by 50.14% to -$4.8 million in 2024, then sank by 374.14% to -$22.6 million in 2025, then jumped by 79.25% to -$4.7 million in 2026.
• The last three EBT figures came in at -$4.7 million (Q1 2026), -$22.6 million (Q4 2025), and -$5.5 million (Q3 2025), per Business Quant data.